A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
Antidepressants, such as Prozac, are already used to treat the condition but Canadian and Italian scientists set out to ...
Hosted on MSN2d
Worrying shortage of antipsychotic drugs in CyprusCyprus is rapidly running out of the antipsychotic drug Seroquel with the higher dosages especially being in short supply since early October, the Cyprus News Agency reported on Wednesday.Seroquel is ...
Chinese actress Zhao Lusi has made her first public appearance following a month-long treatment for depression, capturing ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
A new study from the Texas A&M University School of Public Health provides additional evidence that meditation using ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback